Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Q4 FY2020 Earnings Presentation
14 slides from Myriad Genetics's earnings presentation, Aug 13, 2020
Slide 1: Fiscal Fourth-Quarter 2020 Earnings Call
Myriad Genetics Fiscal Fourth-Quarter 2020 Earnings Call August 13, 2020 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Test Volume Trends
Test Volume Trends Test volume recovered to 75% of anticipated demand by end of 4Q20
Slide 4: Fiscal Fourth-Quarter 2020 Revenue By Product
Fiscal Fourth-Quarter 2020 Revenue By Product Product 4Q20 4Q19 YoY Growth Test Volume Growth ASP Change Hereditary Cancer $39.9 $119.0 (66%) (58%) (20%) GeneSight® $8.5 $29.8 (71%) (69%) (7%) Prenatal Testing $16.6 $25.0 (34%) (11%) (26%) Vectra® $7.2 $12.2 (41%) (42%) 2% Prolaris® $4.5 $6.3 (29%)
Slide 5: Fiscal Fourth-Quarter 2020 Financial Results
Fiscal Fourth-Quarter 2020 Financial Results GAAP Results Adjusted Results 4Q20 4Q19 YoY Growth 4Q20 4Q19 YoY Growth Total Revenue $93.2 $215.4 (57%) $93.2 $215.4 (57%) Gross Profit $56.5 $164.8 (66%) $56.8 $165.4 (66%) Gross Margin 60.6% 76.5% -1590 bps 60.9% 76.8% -1590 bps Operating Income ($68.3
Slide 6: Expanding Sales Team to Target Primary Care Market
Expanding Sales Team to Target Primary Care Market 60% seen by primary care 40% seen by psychiatrists Plans to add 65 new sales reps by end of 1Q21 5M Newly Diagnosed Patients Per Year Who are Candidates for Psychotropic Medicines New LCD expands market by: Covering patients seen by any licensed pro
Slide 7: Myriad Launches GeneSight Direct-to-Patient Sample Collection Kit
Myriad Launches GeneSight Direct-to-Patient Sample Collection Kit
Slide 8: GeneSight Superior to Single-Gene Testing at Predicting Blood Drug Levels
GeneSight Superior to Single-Gene Testing at Predicting Blood Drug Levels N=191 (patients taking citalopram)
Slide 9: riskScore Significantly Modifies Risk Prediction in Mutation Carriers
riskScore® Significantly Modifies Risk Prediction in Mutation Carriers Presentation at San Antonio Breast Cancer Symposium: “Polygenic Breast Cancer Risk Modification in Carriers of High and Intermediate Risk Gene Mutations”
Slide 10: Myriad Launches "Gene" Chatbot To Support Customers in Hereditary Cancer
Myriad Launches “Gene” Chatbot To Support Customers in Hereditary Cancer Can answer over 500,000 health and financial related questions relevant to hereditary cancer testing Interfaces with market leading hereditary cancer quiz Can help a patient find a physician to determine appropriateness of test
Slide 11: myChoice CDx Identified Responders to Olaparib and Receives FDA Approval
myChoice CDx Effectively Identified Responders to Olaparib and Receives FDA Approval in First-Line Maintenance for Ovarian Cancer * Ray-Coquard et al; Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer; The New England Journal of Medicine December 2019 Progression Free Survival (M
Slide 12: Prequel Offers Superior NIPS Testing
Prequel® Offers Superior NIPS Testing Source: Muzzey et al: Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk AMPLIFY technology increases fetal fraction an average of 2.3x an
Slide 13: Four New Commercial Payers Add 26M Covered Lives
Four New Commercial Payers Add 26M Covered Lives 225 Sales Reps 80 Sales Reps Commercial Insurers Medicare Low & Favorable Intermediate Medicare High & Non- Favorable Intermediate
Slide 14: Risk of Radiographic Progression Added to Vectra Test Report
Risk of Radiographic Progression Added to Vectra Test Report